High mobility group box-1 protein as a tumor necrosis factor-independent therapeutic target in rheumatoid arthritis

Arthritis Research and Therapy

Volumn 10, Issue 3, 2008, Pages

  Goldstein, Richard S ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; INFLIXIMAB; INTERLEUKIN 1; RECOMBINANT HIGH MOBILITY GROUP B1 PROTEIN; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ANTIBODY; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTHROSCOPY; DRUG EFFICACY; DRUG TARGETING; EDITORIAL; HUMAN; INFLAMMATION; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; ANIMAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; METABOLISM; METHODOLOGY; NOTE;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG DELIVERY SYSTEMS; HMGB1 PROTEIN; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 44849084206     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2427     Document Type: Editorial

References (10)

1. Sundberg E Grundtman C Klint E Lindberg J Ernestam S Ulfgren K Harris H Andersson U Systemic TNF blockade does not modulate synovial expression of the proinflammatory mediator HMGB1 in rheumatoid arthritis patients - a prospective clinical study Arthritis Res Ther 2008, 10:R33. 10.1186/ ar2387 18346273
2. Maini R St Clair EW Breedveld F Furst D Kalden J Weisman M Smolen J Emery P Harriman G Feldmann M Lipsky P Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant Methotrexate: A randomized phase III trial Lancet 1999, 354:1932-1939. 10.1016/ S0140-6736(99)05246-0 10622295
3. Lipsky PE van der Heijde DM St Clair EW Furst DE Breedveld FC Kalden JR Smolen JS Weisman M Emery P Feldmann M Harriman GR Maini RN Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group Infliximab and methotrexate in the treatment of rheumatoid arthritis New Engl J Med 2000, 343:1594-1602. 10.1056/ NEJM200011303432202 11096166
4. Weinblatt ME Kremer JM Bankhurst AD Bulpitt KJ Fleischmann RM Fox RI Jackson CG Lange M Burge DJ A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving Methotrexate New Eng J Med 1999, 340:253-259. 10.1056/NEJM199901283400401 9920948
5. Taniguchi N Kawahara K Yone K Hashiguchi T Yamakuchi M Goto M Inoue K Yamada S Ijiri K Matsunaga S Nakajima T Komiya S Maruyama I High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine Arthritis Rheum 2003, 48:971-981. 10.1002/art.10859 12687539
6. Kokkola R Li J Sundberg E Aveberger AC Palmblad K Yang H Tracey KJ Andersson U Harris HE Successful treatment of collagen-induced arthritis in mice and rats by targeting extra-cellular high mobility group box chromosomal protein 1 activity Arthritis Rheum 2003, 48:2052-2058. 10.1002/art.11161 12847700
7. Pullerits R Jonsson IM Verdrengh M Bokarewa M Andersson U Erlandsson-Harris H Tarkowski A High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis Arthritis Rheum 2003, 48:1693-1700. 10.1002/art.11028 12794838
8. Andersson U Wang H Palmblad K Aveberger AC Bloom O Erlandsson-Harris H Janson A Kokkola R Zhang M Yang H Tracey KJ High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes J Exp Med 2000, 192:565-570. 2193240 10952726 10.1084/ jem.192.4.565
9. Wang H Bloom O Zhang M Vishnubhakat JM Ombrellino M Che J Frazier A Yang H Ivanova S Borovikova L Manogue KR Faist E Abraham E Andersson J Andersson U Molina PE Abumrad NN Sama A Tracey KJ HMG-1 as a late mediator of endotoxin lethality in mice Science 1999, 285:248-251. 10.1126/science.285.5425.248 10398600
10. Goldstein RS Bruchfeld A Yang L Qureshi AR Gallowitsch-Puerta M Patel NB Huston BJ Chavan S Rosas-Ballina M Gregersen PK Czura CJ Sloan RP Sama AE Tracey KJ Cholinergic anti-inflammatory pathway activity and high mobility group box-1 (HMGB1) serum levels in patients with rheumatoid arthritis Mol Med 2007, 13:210-215. 1899837 17597834 10.2119/ 2006-00108.Goldstein